Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1922430 | 0.94 | ALDH1A1 (0.45) | ALDH1A1LMNAHSD17B10TSHRCYP3A4 | |
| SCHEMBL18098051 | 0.92 | ALDH1A1 (0.46) | ALDH1A1LMNAHSD17B10 | |
| SCHEMBL17636285 | 0.91 | ALDH1A1 (0.42) | ALDH1A1LMNAHSD17B10TSHRCYP3A4 | |
| SCHEMBL17636252 | 0.88 | LMNA (0.40) | ALDH1A1LMNAHSD17B10TSHRCYP3A4 | |
| SCHEMBL2220993 | 0.84 | ALDH1A1 (0.62) | ALDH1A1TSHR | |
| SCHEMBL6857994 | 0.83 | ALDH1A1 (0.42) | ALDH1A1LMNAHSD17B10 | |
| SCHEMBL14607672 | 0.83 | ALDH1A1 (0.50) | ALDH1A1LMNAHSD17B10TSHR | |
| SCHEMBL8277381 | 0.82 | ALDH1A1 (0.54) | ALDH1A1TSHR | |
| SCHEMBL715313 | 0.77 | ALDH1A1 (0.54) | ALDH1A1 | |
| SCHEMBL16541056 | 0.77 | ALDH1A1 (0.54) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110590560-A | Polyol nitrate and rehabilitation treatment application thereof to cardiovascular and cerebrovascular diseases | 江西三艾曲生物科技有限公司 | 2019-12-20 | — | — | CN | claimed |
| US-9023890-B2 | Nitrate esters and their use for the treatment of muscle and muscle related diseases | THE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY (US) | 2015-05-05 | — | — | US | claimed |
| CN-110590560-A | Polyol nitrate and rehabilitation treatment application thereof to cardiovascular and cerebrovascular diseases | 江西三艾曲生物科技有限公司 | 2019-12-20 | — | — | CN | disclosed |
| US-9452117-B2 | Nitrate esters and their use for the treatment of muscle and muscle related diseases | THE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY (US) | 2016-09-27 | — | — | US | disclosed |
| US-9452117-B2 | Nitrate esters and their use for the treatment of muscle and muscle related diseases | THE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY (US) | 2016-09-27 | — | — | US | disclosed |
| US-9452117-B2 | Nitrate esters and their use for the treatment of muscle and muscle related diseases | THE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY (US) | 2016-09-27 | — | — | US | disclosed |
| EP-2329862-B1 | Nitrate esters and their use for the treatment of muscle and muscle related diseases | CHARLOTTE MECKLENBURG HOSPITAL (US) | 2016-03-30 | — | — | EP | disclosed |
| US-9023890-B2 | Nitrate esters and their use for the treatment of muscle and muscle related diseases | THE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY (US) | 2015-05-05 | — | — | US | disclosed |
| US-20120309825-A1 | Nitrate Esters And Their Use For The Treatment Of Muscle And Muscle Related Diseases | THE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY D/B/A CAROLINAS MEDICAL CENTER (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120309825-A1 | Nitrate Esters And Their Use For The Treatment Of Muscle And Muscle Related Diseases | THE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY D/B/A CAROLINAS MEDICAL CENTER (US) | 2012-12-06 | — | — | US | disclosed |
| EP-2529734-A1 | Nitrate esters and their use for the treatment of muscle and muscle related diseases | The Charlotte-Mecklenburg Hospital Authority (US) | 2012-12-05 | — | — | EP | disclosed |
| EP-2329862-A1 | Nitrate esters and their use for the treatment of muscle and muscle related diseases | The Charlotte-Mecklenburg Hospital Authority (US) | 2011-06-08 | — | — | EP | disclosed |
| US-20110130455-A1 | Nitrate Esters and Their Use For The Treatment of Muscle and Muscle Related Diseases | THE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY D/B/A CAROLINAS MEDICAL CENTER | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309825-A1 | Nitrate Esters And Their Use For The Treatment Of Muscle And Muscle Related Diseases | TNNC1, TNNI3, TNNT2 | ALDH1A1 1718/4885LMNA 568/4885HSD17B10 125/4885 |
| US-20110130455-A1 | Nitrate Esters and Their Use For The Treatment of Muscle and Muscle Related Diseases | TNNC1, TNNI3, TNNT2 | ALDH1A1 1657/4885LMNA 613/4885HSD17B10 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.